120 related articles for article (PubMed ID: 36240468)
1. High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course.
O'Donoghue DF; Truong HL; Finnes HD; McDonald JS; May HP; Ansell SM; Bennani NN; Habermann TM; Inwards DJ; Johnston PB; Khurana A; Lin Y; Micallef IN; Nowakowski GS; Paludo J; Porrata LF; Thanarajasingam G; Thompson CA; Villasboas JC; Wang Y; Witzig TE; Leung N
JCO Oncol Pract; 2022 Dec; 18(12):e1908-e1917. PubMed ID: 36240468
[TBL] [Abstract][Full Text] [Related]
2. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.
Barreto JN; Peterson KT; Barreto EF; Mara KC; Dierkhising RA; Leung N; Witzig TE; Thompson CA
Support Care Cancer; 2021 Sep; 29(9):5293-5301. PubMed ID: 33661366
[TBL] [Abstract][Full Text] [Related]
3. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
Gros L; Roldán A; Cabero-Martínez A; Domínguez-Pinilla N; de la Fuente A; González-Barca E; Tasso M; Torrent M; Gallardo E; Del Cerro I; Giró-Perafita A; Badia X
J Oncol Pharm Pract; 2023 Jun; 29(4):794-801. PubMed ID: 35147457
[TBL] [Abstract][Full Text] [Related]
4. Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients.
Wang Y; Wei L; Guan Y; Wang Q; Xie Q; Hao C
Ren Fail; 2020 Nov; 42(1):1111-1117. PubMed ID: 33164656
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
Amitai I; Rozovski U; El-Saleh R; Shimony S; Shepshelovich D; Rozen-Zvi B; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2020 Oct; 38(4):584-588. PubMed ID: 32506594
[TBL] [Abstract][Full Text] [Related]
6. High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Predictors of Delayed Clearance and the Effect of Increased Hydration Rate on Methotrexate Clearance.
Chen AR; Wang YM; Lin M; Kuo DJ
Cureus; 2020 Jun; 12(6):e8674. PubMed ID: 32699674
[TBL] [Abstract][Full Text] [Related]
7. Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.
DeFino CE; Barreto JN; Pawlenty AG; Ruff MW; Carabenciov ID; Mara KC; Thompson CA
Pharmacotherapy; 2021 May; 41(5):430-439. PubMed ID: 33655525
[TBL] [Abstract][Full Text] [Related]
8. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma.
Sun K; Tao H; Ding T; Li Z; Qiu X; Zhong M; Wu Z
J Clin Pharm Ther; 2022 Dec; 47(12):2196-2204. PubMed ID: 36259502
[TBL] [Abstract][Full Text] [Related]
10. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for predicting high dose methotrexate associated acute kidney injury in children with acute lymphoblastic leukemia.
Li H; Xu Q; Wang Y; Chen K; Li J
Cancer Chemother Pharmacol; 2020 Jan; 85(1):95-103. PubMed ID: 31676986
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphoma.
Rice ML; Barreto EF; Rule AD; Martin CE; Truong HL; Mara KC; Kashani KB; Thompson CA; Witzig TE; Barreto JN
Pharmacotherapy; 2024 Jan; 44(1):4-12. PubMed ID: 37926860
[TBL] [Abstract][Full Text] [Related]
12. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
13. Identification of Risk Factors in High-Dose Methotrexate-Induced Acute Kidney Injury in Childhood Acute Lymphoblastic Leukemia.
Cheng DH; Lu H; Liu TT; Zou XQ; Pang HM
Chemotherapy; 2018 Apr; 63(2):101-107. PubMed ID: 29672292
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for acute kidney injury after high-dose methotrexate therapy: a single-center study and narrative review.
Liang CA; Su YC; Lin SJ; Tsai TH
Eur J Clin Pharmacol; 2023 Jun; 79(6):789-800. PubMed ID: 37060460
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between postoperative immediate serum albumin level and postoperative acute kidney injury after major abdominal surgery in critically ill patients].
Li W; Li N; Li S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Aug; 33(8):955-961. PubMed ID: 34590563
[TBL] [Abstract][Full Text] [Related]
16. [Elevated serum lactic acid level is an independent risk factor for the incidence and mortality of sepsis-associated acute kidney injury].
Gong C; Jiang Y; Tang Y; Liu F; Shi Y; Zhou H; Xie K
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Jul; 34(7):714-720. PubMed ID: 36100409
[TBL] [Abstract][Full Text] [Related]
17. Body Surface Area Dosing of High-Dose Methotrexate Should Be Reconsidered, Particularly in Overweight, Adult Patients.
Gallais F; Oberic L; Faguer S; Tavitian S; Lafont T; Marsili S; Brice A; Chatelut E; Puisset F
Ther Drug Monit; 2021 Jun; 43(3):408-415. PubMed ID: 32925658
[TBL] [Abstract][Full Text] [Related]
18. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers.
Khera S; Kapoor R; Pramanik SK
Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952
[TBL] [Abstract][Full Text] [Related]
19. Outpatient administration of high-dose methotrexate in adults without drug monitoring - a case-control study of risk factors for acute kidney injury.
Alves C; Pereira J; Rego EM; Rocha V; Silva WF
Hematol Transfus Cell Ther; 2023 Dec; ():. PubMed ID: 38233304
[TBL] [Abstract][Full Text] [Related]
20. A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma.
Fox E; Busch C; DeBernardo A; Segers B; Gottschalk J; Womer R; Balamuth N; Bagatell R; Balis F
Cancer Chemother Pharmacol; 2021 Jun; 87(6):807-815. PubMed ID: 33677616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]